Citi maintains 'buy' on AstraZeneca with £170 target, cites sector-best pipeline

1 month ago 25

Proactive

Wed, February 11, 2026 astatine 9:45 AM CST 1 min read

Citi maintains 'buy' connected AstraZeneca with £170 target, cites sector-best pipeline

Double-digit net outlook and beardown proceedings momentum enactment apical prime status

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) remains a apical prime astatine Citi pursuing full-year results and 2026 guidance that the slope described arsenic “reassuring”, with a reiterated people terms of £170 and unchanged net forecasts.

Management confirmed expectations for debased double-digit net maturation successful 2026, aligning with consensus, portion the mean single- to precocious single-digit gross outlook was up of marketplace forecasts.

Citi continues to forecast AstraZeneca exceeding its $80 cardinal gross people for 2030, estimating $82 billion.

Although fourth-quarter operating income came successful 8% beneath consensus, Citi attributed the shortfall to a one-off royalty buyout. Management’s reaffirmation of its mid-30s borderline people helped easiness concerns.

The pipeline remains the strongest successful the sector, with much than 20 signifier III readouts expected successful 2026.

Key milestones see tozorakimab for COPD (Q1), efzofitimod for hypophosphatasia (Q2), Wainua successful ATTR-CM and camizestrant successful bosom crab (Q3), and datopotamab successful lung crab successful the 2nd half.

AZ besides has 5 caller signifier III proceedings launches planned, including elecglipron, an oral GLP-1 therapy.

In day trading, the shares were up 1.2% at 14,340p.